Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Epilepsy Res ; 83(1): 44-51, 2009 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-18977120

RESUMO

Levetiracetam (LEV), a newer antiepileptic drug (AED) useful for several epilepsy syndromes, binds to SV2A. Identifying genetic variants that influence response to LEV may allow more tailored use of LEV. Obvious candidate genes are SV2A, SV2B and SV2C, which encode the only known binding site, synaptic vesicle protein 2 (SV2), with LEV binding to the SV2A isoform. SV2A is an essential protein as homozygous SV2A knockout mice appear normal at birth but fail to grow, experience severe seizures and die by 3 weeks. We addressed characterising AED response issues in pharmacogenetics and whether variation in these genes associates with response to LEV in two independent cohorts with epilepsy. We also investigated whether variation in these three genes associated with epilepsy predisposition in two larger cohorts of patients with various epilepsy phenotypes. Common genetic variation in SV2A, encoding the actual binding site of LEV, was fully represented in this study whereas SV2B and SV2C were not fully covered. None of the polymorphisms tested in SV2A, SV2B or SV2C influence LEV response or predisposition to epilepsy. We found no association between genetic variation in SV2A, SV2B or SV2C and response to LEV or epilepsy predisposition. We suggest this study design may be used in future pharmacogenetic work examining AED or LEV efficacy. However, different study designs would be needed to examine common variation with minor effect sizes, or rare variation, influencing AED or LEV response or epilepsy predisposition.


Assuntos
Anticonvulsivantes/uso terapêutico , Epilepsia/tratamento farmacológico , Epilepsia/genética , Predisposição Genética para Doença , Glicoproteínas de Membrana/genética , Proteínas do Tecido Nervoso/genética , Piracetam/análogos & derivados , Adulto , Estudos de Coortes , Epilepsia do Lobo Temporal/tratamento farmacológico , Epilepsia do Lobo Temporal/genética , Feminino , Variação Genética , Genótipo , Hipocampo/patologia , Humanos , Irlanda , Levetiracetam , Masculino , Piracetam/uso terapêutico , Polimorfismo Genético/genética , Vesículas Sinápticas/genética , Reino Unido
2.
J Bacteriol ; 183(3): 830-4, 2001 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-11208779

RESUMO

Saccharomyces cerevisiae normally will not take up sterols from the environment under aerobic conditions. A specific mutant, upc2-1, of the predicted transcriptional activator UPC2 (YDR213w) has been recognized as a strain that allows a high level of aerobic sterol uptake. Another predicted transcriptional activator, the YLR228c gene product, is highly homologous to Upc2p. In fact, at the carboxy terminus 130 of the last 139 amino acids are similar between the two proteins. Since these proteins are very similar, the effect of mutations in the YLR228c open reading frame (ORF) was compared with like alterations in UPC2. First, the YLR228c ORF was insertionally inactivated and crossed with various UPC2 constructs. Deletion of YLR228c and UPC2 in combination resulted in nonviability, suggesting that the two proteins have some essential overlapping function. The upc2-1 point mutation responsible for aerobic sterol uptake was duplicated in the homologous carboxy region of the YLR228c ORF using site-directed mutagenesis. This mutation on a high-copy vector resulted in an increase in sterol uptake compared to an isogenic wild-type strain. The combination of both point mutations resulted in the greatest level of aerobic sterol uptake. When the YLR228c point mutation was expressed from a low-copy vector there was little if any effect on sterol uptake. Gas chromatographic analysis of the nonsaponifiable fractions of the various strains showed that the major sterol for all YLR228c and UPC2 combinations was ergosterol, the consensus yeast sterol.


Assuntos
Proteínas de Saccharomyces cerevisiae , Saccharomyces cerevisiae/genética , Esteróis/metabolismo , Transativadores/genética , Sequência de Aminoácidos , Transporte Biológico , Proteínas Fúngicas/genética , Dados de Sequência Molecular , Mutagênese Insercional , Mutação Puntual , Homologia de Sequência de Aminoácidos
3.
J Bacteriol ; 180(16): 4177-83, 1998 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-9696767

RESUMO

Aerobically growing wild-type strains of Saccharomyces cerevisiae are unable to take exogenously supplied sterols from media. This aerobic sterol exclusion is vitiated under anaerobic conditions, in heme-deficient strains, and under some conditions of impaired sterol synthesis. Mutants which can take up sterols aerobically in heme-competent cells have been selected. One of these mutations, designated upc2-1, gives a pleiotropic phenotype in characteristics as diverse as aerobic accumulation of sterols, total lipid storage, sensitivity to metabolic inhibitors, response to altered sterol structures, and cation requirements. During experiments designed to ascertain the effects of various cations on yeast with sterol alterations, it was observed that upc2-1 was hypersensitive to Ca2+. Using resistance to Ca2+ as a screening vehicle, we cloned UPC2 and showed that it is YDR213W, an open reading frame on chromosome IV. This belongs to a fungal regulatory family containing the Zn(II)2Cys6 binuclear cluster DNA binding domain. The single guanine-to-adenine transition in upc2-1 gives a predicted amino acid change from glycine to aspartic acid. The regulatory defect explains the semidominance and pleiotropic effects of upc2-1.


Assuntos
Genes Fúngicos , Genes Reguladores , Mutação , Proteínas de Saccharomyces cerevisiae , Saccharomyces cerevisiae/genética , Esteróis/metabolismo , Transativadores/genética , Sequência de Aminoácidos , Sequência de Bases , Cálcio/metabolismo , Proteínas Fúngicas/genética , Teste de Complementação Genética , Dados de Sequência Molecular , Fases de Leitura Aberta , Saccharomyces cerevisiae/metabolismo , Transativadores/metabolismo
4.
Appl Environ Microbiol ; 64(6): 2262-5, 1998 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-9603845

RESUMO

Cryptosporidium parvum is a protozoan parasite that causes the disease cryptosporidiosis in a variety of mammals, including neonatal calves and humans. Millions of oocysts are shed during acute cryptosporidiosis, and zoonotic transmission is inferred, though not proven, to be a general phenomenon. Very little is known about the degree of strain variation exhibited by bovine and human isolates, though such knowledge would enable the amount of bovine-to-human transmission to be more precisely analyzed. This research was initiated to determine whether variations exist among bovine strains isolated from a localized geographic area, the watershed of the Red River of the North. Sixteen strains were isolated and compared to each other and to two human and two calf strains from Australia by randomly amplified polymorphic DNA PCR. A statistical analysis of the data indicated that the isolates belonged to four different groups of strains.


Assuntos
Bovinos/parasitologia , Cryptosporidium parvum/genética , Cryptosporidium parvum/isolamento & purificação , DNA de Protozoário/genética , Animais , Sequência de Bases , Doenças dos Bovinos/parasitologia , Criptosporidiose/parasitologia , Criptosporidiose/veterinária , Cryptosporidium parvum/classificação , Primers do DNA/genética , Reservatórios de Doenças , Variação Genética , Humanos , Técnica de Amplificação ao Acaso de DNA Polimórfico , Zoonoses
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...